Special Emphasis Panel for Basic Cancer Mechanism and Therapeutics – BCMT (81)

Topics

• Immune signaling pathways and deregulation in the tumor microenvironment (immune suppression, immune tolerance, immune surveillance, immune evasion).
• Molecular and cellular aspects of interactions between tumors, stromal cells and extracellular matrix with an emphasis on tumor cell biology in tumorigenesis and metastatic niche.
• Microbiome effects on tumor growth and tumor immune microenvironment.
• Neuronal interactions between molecular and cellular components of tumor stromal and immune microenvironments
• Model systems and novel technologies for studying cancer immunobiology; and tumor cells in the context of a tissue-like and in vivo environment including physiologically responsive in vitro 3D systems, organotypic models.
• Computational, data mining and machine learning approaches for new immune target and tumor associated antigen discovery. 

Shared Interests and Overlaps

• There are shared interests with Basic Cancer Immunobiology (BCIB)  in tumor immunology and immune response to cancer. Applications focusing on immune response in cancer, tumor immunity or immune regulatory mechanisms may be reviewed in BCIB. Applications that focus on novel model systems and computational approaches for studying tumor immune cell functions may be in ZRG1 BCMT-80.
• There are shared interests with Tumor Host Interactions (THI)  and BCIB in tumor metabolism and intercellular communications. Applications that focus on metabolism in the interactions between tumor cells and cells in the surrounding microenvironment may be reviewed in THI. Applications that focus the microbiome effects on tumor growth can be reviewed in ZRG1 BCMT-80.
• There are shared interests with Translational Immuno-Oncology (TIO) in novel technology development. . Applications that involve novel reagents such as antibodies, vaccines or predictive biomarkers in immunotherapies may be reviewed in TIO. Applications focused on basic immune mechanisms associated with new technologies or proof of concept may be reviewed in ZRG1 BCMT-80
• There are shared interests with Therapeutic Immune Regulation (TIR)  and Translational Immuno-Oncology (TIO) and Cellular Immunotherapy of Cancer (CIC)  in immune response to cancer and interactions with tumor cells. Applications focused on therapeutic strategies for cell-based immune therapies may be reviewed in CIC.  Applications that focus on immunotherapies to improve response or overcome resistance to immunotherapy, may be reviewed in TIR. Applications focused on mechanistic understanding or technology development of cell-based immune therapies or use neoplastic agents as tools to study the immune response in cancer, tumor immunity or immune regulatory mechanisms may be reviewed in ZRG1 BCMT-80.

There are shared interests with Mechanisms of Established Cancer Therapeutics A, B, C (MCTA, B, C) in identification of cancer therapeutic targets. Applications that focus mechanistic studies of the effects of anti-neoplastic agents on the tumor microenvironment or the identification of new immunologic targets to improve, validate or predict the efficacy of targeted or conventional therapy may be reviewed in MCTA,B,C.  Applications that focus on the tumor microenvironment, tumor immunobiology and identification of novel immunologic targets using neoplastic agents as tools may be reviewed in ZRG1 BCMT-80.